PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
نویسندگان
چکیده
منابع مشابه
PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
Lung cancer is the leading cause of cancer death in males and the second leading cause of death in females worldwide. Non-small-cell lung cancer (NSCLC) is the main pathological type of lung cancer, and most newly diagnosed NSCLC patients cannot undergo surgery because the disease is already locally advanced or metastatic. Despite chemoradiotherapy and targeted therapy improving clinical outcom...
متن کاملPD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
The programmed death 1 (PD-1) pathway is an immune checkpoint that has been implicated in tumoral immune escape, and has emerged as a major focus of immunotherapy in non-small cell lung cancer (NSCLC). Multiple agents have progressed through clinical development in recent years, including antibodies targeting both PD-1 and its key ligand, programmed death ligand 1 (PD-L1). This article reviews ...
متن کاملPD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
Immunotherapy with checkpoint inhibitors, allowing recovery of effector cells function, has demonstrated to be highly effective in many tumor types and represents a true revolution in oncology. Recently, the anti-PD1 agent pembrolizumab was granted FDA approval for the first line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors show PD-L1 expression in ≥ 50% o...
متن کاملExpression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
Binding of programmed death-1 (PD-1) with its ligands (PD-L1/2) transmits a co-inhibitory signal in activated T-cells that promotes T-cell exhaustion, leading to tumor immune evasion. The efficacy of antibodies targeting PD-1 and PD-L1 has led to a paradigm shift in lung cancer treatment but the prognostic and predictive value of tumor PD-L1 expression remains controversial. Evaluating PD-1, PD...
متن کاملPD-L1 in non-small-cell lung cancer: the third target for immunotherapy.
www.thelancet.com Published online March 9, 2016 http://dx.doi.org/10.1016/S0140-6736(16)00700-5 1 Advanced-stage non-small-cell lung cancer (NSCLC) has a dismal prognosis. At disease presentation, more than 50% of patients have metastatic disease and, despite advances in chemotherapy and targeted therapy, median overall survival is less than 1 year. For patients who progress on fi rst-line sta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: OncoTargets and Therapy
سال: 2016
ISSN: 1178-6930
DOI: 10.2147/ott.s94993